title: Prospective investigation of nasal mupirocin, hexachlorophene body wash, and systemic antibiotics for prevention of recurrent community-associated methicillin-resistant Staphylococcus aureus infections.
abstract: Recurrent community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections are an increasingly common problem. However, there are no data on the efficacy of decolonization regimens. We prospectively evaluated 31 patients with recurrent CA-MRSA skin infections who received nasal mupirocin, topical hexachlorophene body wash, and an oral anti-MRSA antibiotic. The mean number of MRSA infections after the intervention decreased significantly from baseline (0.03 versus 0.84 infections/month, P = <0.0001). This regimen appears promising at preventing recurrent CA-MRSA infections.
authors.affiliation: Harbor-UCLA Medical Center, Torrance, California, USA. Lgmiller@ucla.edu
authors.forename: Loren G
authors.initials: LG
authors.lastname: Miller
authors.forename: Jennifer
authors.initials: J
authors.lastname: Tan
authors.forename: Samantha J
authors.initials: SJ
authors.lastname: Eells
authors.forename: Esther
authors.initials: E
authors.lastname: Benitez
authors.forename: Allen B
authors.initials: AB
authors.lastname: Radner
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D005260:Female; D006582:Hexachlorophene / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008875:Middle Aged; D016712:Mupirocin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D016712:Mupirocin; D006582:Hexachlorophene
references.citation: Clin Infect Dis. 2007 Feb 15;44(4):483-92
references.pmid: 17243049
references.citation: Clin Infect Dis. 2011 Feb 1;52(3):285-92
references.pmid: 21217178
references.citation: Arch Intern Med. 2008 Jul 28;168(14):1585-91
references.pmid: 18663172
references.citation: N Engl J Med. 2008 Mar 13;358(11):1200-1
references.pmid: 18337614
references.citation: Am J Infect Control. 2010 May;38(4):324-8
references.pmid: 20420965
references.citation: Arch Intern Med. 1996 May 27;156(10):1109-12
references.pmid: 8638999
references.citation: Dis Mon. 2008 Dec;54(12):801-6
references.pmid: 18996283
references.citation: Obstet Gynecol. 2005 Sep;106(3):461-5
references.pmid: 16135574
references.citation: Pediatr Infect Dis J. 2005 May;24(5):457-8
references.pmid: 15876948
references.citation: Clin Infect Dis. 2007 Feb 15;44(4):471-82
references.pmid: 17243048
references.citation: Infect Dis Clin North Am. 2009 Mar;23(1):35-52
references.pmid: 19135915